To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
News | Institutional | Toxicology | Diagnosis and innovative treatment
A SIMOPRO project supported by SATT Paris-Saclay: in vivo validation of the efficacy of the DTR8 molecule, developed and patented at SIMOPRO (Department of Medicines and Technologies for Health) in collaboration with Inserm, as a treatment for glomerulonephritis rapidly progressive.
Daniel Gillet (SIMOPRO) and his team exploited the natural ability of diphtheria toxin to bind to the precursor of Heparin-binding Epidermal Growth Factor (Heparin Binding-Epidermal Growth Factor) to develop a very potent selective inhibitor of this growth factor: the DTR8 protein. In collaboration with Inserm's nephrologist Pierre-Louis Tharaux, DTR8 has shown efficacy in monkeys to treat rapidly progressive glomerulonephritis, a rare renal disease in which overexpression of the growth factor is directly involved. A patent covering Europe, the United States and Japan has been issued.Accompanied by the institute's Valo cell, and with the help of a first grant from the Rare Diseases Foundation, Daniel Gillet and his team set up a consortium of Inserm, SATT Paris-Saclay and an investor private, to fund in vivo proof of concept in a pig model representative of human pathology. With the maturation agreement just signed, the two-year program can now begin.At the end of the program, and in the event of a consolidated demonstration of the effectiveness of the therapeutic protein DTR8 against rapidly progressive glomerulonephritis, the objective will be to license the patent to a pharmaceutical manufacturer or to create a start-up.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.